Lipid profiles improved, with HDL cholesterol increasing by 10.81 mg/dL and triglycerides decreasing by 29.20 mg/dL
Intranasal administration of PT-141 has been studied and shows approximately 25% bioavailability compared to subcutaneous injection, but is not the standard route in published protocols
Why Semaglutide Makes Unhealthy Snacking Less Tempting Semaglutide's mechanism directly addresses the neurological drivers of snacking behavior
5, 6 Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1, 7, 8 leading to investigations into its potential for the treatment of obesity
Planned REDF publications will therefore include sections on study-design templates, control strategies, and recommended reporting elements tailored to endocrine and metabolic research contexts